Alembic Pharmaceuticals Limited announced its financial results for the quarter and half-year ended September 30, 2026. The company reported a substantial 36% year-on-year revenue growth to ₹26.03 billion in Q2 FY27. EBITDA and PAT also saw significant increases of 520 bps and 81% respectively. All business segments, including India, US, API, and Ex-US, registered double-digit growth, showcasing a robust performance across the board.
Alembic Pharmaceuticals Q2 FY27 Financial Highlights
Alembic Pharmaceuticals Limited has unveiled its financial performance for the second quarter and the first half of the fiscal year 2027, ending on September 30, 2026. The company demonstrated strong growth across its business verticals, driven by consistent execution and market expansion.
Revenue and Profitability Surge
In Q2 FY27, the company’s Revenue reached ₹26.03 billion, marking an impressive 36% increase compared to the same period in the previous year. The EBITDA Margin expanded by 520 basis points, with EBITDA growing by 78% YoY to ₹5.78 billion. Profit After Tax (PAT) witnessed a significant surge of 81% YoY, reaching ₹3.35 billion. The Gross Margin stood at a healthy 73.7%, with a 70 bps YoY improvement. R&D Spend was maintained at 8% of revenue.
Segmental Performance
All business segments of Alembic Pharmaceuticals reported double-digit growth in Q2 FY27. The India Branded Business grew by 14%, contributing significantly to the overall performance. The US business experienced exceptional growth of 77%. The API business also showed robust expansion with a 39% YoY increase, while the Ex-US business grew by 12%.
Key Business Drivers
The company highlighted several key drivers for its performance, including revenue growth across all businesses, core margin expansion supported by R&D funding for specialty portfolios and the US branded platform, and strong execution momentum across markets. The Indian chronic portfolio and US Branded traction building were noted as key areas of focus. For the half-year ended H1 FY27, the total revenue stood at ₹47.53 billion, a 31% YoY growth.
R&D and Infrastructure
Alembic Pharmaceuticals continues its investment in building product pipelines and maintained its R&D expenditure at 8% of revenue in Q2 FY27. The company has a robust infrastructure with multiple USFDA and WHO-audited facilities. ESG initiatives remain a focus, with goals set for Net Zero by 2050 and water neutrality by 2027, alongside significant progress in tree plantation and recycling efforts.
Yearly Financial Outlook
Looking ahead, the company’s yearly financial projections show a consistent upward trend in Revenue, EBITDA, and Net Profit. The EBITDA margin is expected to remain strong, and ROCE is projected to be around 15-16%.
Source: BSE
